3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
6
Gastrointestinal
6
Endocrine
6
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
1872
Triple Negative Breast Neoplasms
126
Neoplasms
74
Ovarian Neoplasms
56
Neoplasm Metastasis
55
Colorectal Neoplasms
54
Prostatic Neoplasms
53
Lung Neoplasms
51
Stomach Neoplasms
45
Pancreatic Neoplasms
43
Motor Activity
41
Colonic Neoplasms
41
Lymphedema
35
Breast Cancer Female
32
Advanced Breast Cancer
32
Carcinoma, Non-Small-Cell Lung
31
Endometrial Neoplasms
28
Melanoma
27
Breast Diseases
26
Head and Neck Neoplasms
25
Cardiotoxicity
25
HER2-positive Breast Cancer
22
Uterine Cervical Neoplasms
21
Brain Neoplasms
21
Breast Cancer Lymphedema
20
Pain
19
Fatigue
19
Esophageal Neoplasms
19
Breast Neoplasms, Male
19
Urinary Bladder Neoplasms
18
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastro-enteropancreatic neuroendocrine tumor
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled